Real-world community oncology data link GLP-1 drugs to 34% lower death risk across cancers, prompting calls for prospective trials.
Jess Paulus, ScD
Advertisement
Articles by Jess Paulus, ScD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
FDA Grants Breakthrough Status to Olomorasib in Pancreatic Cancer
3
Dr Vincent Ma: CTGTAC's 10-3 Vote on RP1/Nivo Is “Encouraging”
4
Neoadjuvant iSBRT Plus Durvalumab Boosts pCR in Cold Breast Tumors
5